Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
← catalyst calendarNCT06937099 · readout ≤ 651 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
290estimated
Sites
186
Countries
Austria, Belgium, Brazil +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-26 | actual | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Crohn's Disease
- Obesity or Overweight
Interventions
- Drug: Mirikizumab — also filed as LY3074828
- Drug: Mirikizumab — also filed as LY3074828
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction
measured Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed